Bali Peptide Lab vs Primogen: Research Vial Prices & COAs
Lower listed prices on two matched research vials and access to available reports make Bali Peptide Lab worth comparing with Primogen.
Published by Bali Peptide Lab, a supplier included in this comparison. Public website information reviewed on 12 October 2026. Prices and terms can change; confirm current availability and the final order total.
| Published item | Bali Peptide Lab | Primogen |
|---|---|---|
| BPC-157 10 mg, one vial | IDR 1,140,600 | IDR 1,490,000 |
| GHK-Cu 100 mg, one vial | IDR 876,200 | IDR 1,490,000 |
| COA access | Linked reports for selected listings | Supplier reports on request where provided |
Sources checked
Comparing Bali Peptide Lab with Primogen is most useful when you start with the exact research vial you need. For BPC-157 10 mg and GHK-Cu 100 mg, the reviewed catalogue prices favour Bali Peptide Lab. That is a specific purchasing advantage for those presentations, rather than a claim that every BPL product is cheaper or analytically superior.
Where Bali Peptide Lab offers a price advantage
The listed difference for one BPC-157 10 mg vial is IDR 349,400. For one GHK-Cu 100 mg vial it is IDR 613,800. These are comparisons of advertised base prices for matching labelled amounts. They do not account for vouchers, bundled supplies, multi-vial offers or a separately agreed quote. Price per listed vial is a budget measure, not a laboratory result.
Primogen also advertises a first-order offer and included bacteriostatic water. Its catalogue includes presentations beyond the BPL range. Those may matter to your purchasing list, so compare the complete basket rather than assuming the lower vial price settles every order. Ask whether any promotion applies to the exact items and whether the quoted total includes fulfilment.
Public documentation can reduce enquiry steps
BPL links the available BPC-157 10 mg Janoshik report from the product page and provides a certificate library. You can read that document before opening an order conversation. Primogen says it shares supplier COAs on request where suppliers provide them. For a researcher preparing purchasing records, directly accessible documents can make the initial review easier.
This advantage has a clear boundary: BPL does not publish a matching report for every product. A report must be evaluated for the sample it identifies, and its relationship to the offered batch should be confirmed. A company name, logo or purity headline cannot substitute for that connection. Do not assume the GHK-Cu listing has a report merely because another BPL product does.
Decide on the purchasing record you need
Before requesting a quote, put the compound, amount per vial, vial count and required documentation in one short list. Then check the current BPL product page and the corresponding Primogen presentation. Keep your laboratory specification separate from the supplier's descriptive research categories; similar catalogue labels do not establish interchangeable materials.
Why choose BPL for these research orders?
Bali Peptide Lab is a strong option when your priority is the lower reviewed base price on either of these matched vials and a product page that puts the amount, IDR price, current stock and available documentation together. Use the live listing for the next stock check. The comparison table is a dated price record, not a reservation or a guarantee that a vial remains available.
Both suppliers describe research-use products. This comparison concerns procurement, documentation and cost. It does not recommend a compound for personal use or claim that a lower price predicts experimental performance.
Plan your order
Use current product information and confirm the receiving arrangements with the team before dispatch.
- Check BPC-157 10 mg price, stock and report →
- Review GHK-Cu 100 mg in Bali →
- Compare BPL with BioRelix →
- Confirm Bali delivery arrangements →
Our Approach
Evidence before assumption.
TAM Global Research focuses on transparent documentation, careful scientific interpretation and clear distinction between what available evidence supports and what requires further verification.
Explore our quality standards